JP2021532060A - 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム - Google Patents

炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム Download PDF

Info

Publication number
JP2021532060A
JP2021532060A JP2020560463A JP2020560463A JP2021532060A JP 2021532060 A JP2021532060 A JP 2021532060A JP 2020560463 A JP2020560463 A JP 2020560463A JP 2020560463 A JP2020560463 A JP 2020560463A JP 2021532060 A JP2021532060 A JP 2021532060A
Authority
JP
Japan
Prior art keywords
seq
antibody
binding fragment
antigen
fragment according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020560463A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019212899A5 (https=
JP2021532060A5 (https=
Inventor
ビルズボロー，ジャニーン
ピー． マクガヴァン，ダーモット
タルガン，ステファン
ポダール，アルカ
ワトキンス，ジェフリー，ディー．
ディッカーソン，シンディー，ティー．
Original Assignee
シーダーズ—シナイ メディカル センター
シーダーズ―シナイ メディカル センター
プロメテウス バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーダーズ—シナイ メディカル センター, シーダーズ―シナイ メディカル センター, プロメテウス バイオサイエンシーズ，インク． filed Critical シーダーズ—シナイ メディカル センター
Publication of JP2021532060A publication Critical patent/JP2021532060A/ja
Publication of JPWO2019212899A5 publication Critical patent/JPWO2019212899A5/ja
Publication of JP2021532060A5 publication Critical patent/JP2021532060A5/ja
Priority to JP2024090213A priority Critical patent/JP7832987B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020560463A 2018-04-30 2019-04-26 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム Pending JP2021532060A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024090213A JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862664720P 2018-04-30 2018-04-30
US62/664,720 2018-04-30
US201862681557P 2018-06-06 2018-06-06
US62/681,557 2018-06-06
US201862784179P 2018-12-21 2018-12-21
US62/784,179 2018-12-21
PCT/US2019/029402 WO2019212899A1 (en) 2018-04-30 2019-04-26 Methods and systems for selection and treatment of patients with inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090213A Division JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Publications (3)

Publication Number Publication Date
JP2021532060A true JP2021532060A (ja) 2021-11-25
JPWO2019212899A5 JPWO2019212899A5 (https=) 2022-05-09
JP2021532060A5 JP2021532060A5 (https=) 2022-05-09

Family

ID=68386125

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560463A Pending JP2021532060A (ja) 2018-04-30 2019-04-26 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム
JP2024090213A Active JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024090213A Active JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Country Status (21)

Country Link
US (2) US12305236B2 (https=)
EP (2) EP4296285A3 (https=)
JP (2) JP2021532060A (https=)
KR (2) KR20210013062A (https=)
CN (1) CN112368301B (https=)
AU (1) AU2019261933B2 (https=)
CA (1) CA3098720A1 (https=)
DK (1) DK3774897T5 (https=)
ES (1) ES2962715T3 (https=)
FI (1) FI3774897T3 (https=)
HR (1) HRP20231367T1 (https=)
HU (1) HUE063908T2 (https=)
LT (1) LT3774897T (https=)
MA (1) MA52251A (https=)
MD (1) MD3774897T2 (https=)
PL (1) PL3774897T3 (https=)
PT (1) PT3774897T (https=)
RS (1) RS64747B1 (https=)
SI (1) SI3774897T1 (https=)
TW (1) TW202003573A (https=)
WO (1) WO2019212899A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
ES2962715T3 (es) 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
KR20210130168A (ko) * 2019-02-08 2021-10-29 세다르스-신나이 메디칼 센터 Il18r1을 표적화하는 염증성 질환의 치료를 위한 방법, 시스템 및 키트
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
CA3197828A1 (en) * 2020-11-13 2022-05-19 Laurens Kruidenier Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4256086A4 (en) * 2020-12-01 2025-01-15 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
EP4562038A1 (en) * 2022-07-27 2025-06-04 Cephalon LLC Anti-tl1a antibody formulations
CA3262839A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503319A (ja) * 2000-08-08 2005-02-03 イミュネックス・コーポレーション Ｃｄ３０またはｃｄ３０ｌのアンタゴニストを使用する自己免疫および慢性炎症性状態の処置法
US20180110855A1 (en) * 2016-10-26 2018-04-26 Cedars-Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
AU2010244640A1 (en) * 2009-03-27 2011-08-11 Merck Serono S.A. Genetic severity markers in Multiple Sclerosis
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011020906A2 (en) * 2009-08-21 2011-02-24 INSERM (Institut National de la Santé et de la Recherche Médicale) sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
JP6124800B2 (ja) 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
CN117264057A (zh) * 2012-04-27 2023-12-22 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
AU2013271336B2 (en) 2012-06-04 2017-11-30 Centre For Digestive Diseases Compositions and methods for treating Crohn's Disease and related conditions and infections
EP3389781B1 (en) 2015-12-15 2021-08-11 University of Miami Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same
ES2962715T3 (es) 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503319A (ja) * 2000-08-08 2005-02-03 イミュネックス・コーポレーション Ｃｄ３０またはｃｄ３０ｌのアンタゴニストを使用する自己免疫および慢性炎症性状態の処置法
US20180110855A1 (en) * 2016-10-26 2018-04-26 Cedars-Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, vol. 150, JPN6023019395, 2016, pages 1196 - 1207, ISSN: 0005253273 *
JID, vol. 211, JPN6023019396, 2015, pages 968 - 977, ISSN: 0005253274 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物

Also Published As

Publication number Publication date
EP4296285A2 (en) 2023-12-27
EP3774897A4 (en) 2022-02-16
US20210238684A1 (en) 2021-08-05
JP2024133462A (ja) 2024-10-02
CN112368301B (zh) 2025-12-02
KR20250111409A (ko) 2025-07-22
PT3774897T (pt) 2023-11-10
US12305236B2 (en) 2025-05-20
CA3098720A1 (en) 2019-11-07
CN112368301A (zh) 2021-02-12
DK3774897T3 (da) 2023-11-06
FI3774897T3 (fi) 2023-11-03
HUE063908T2 (hu) 2024-02-28
EP3774897B1 (en) 2023-09-27
MA52251A (fr) 2021-02-17
DK3774897T5 (da) 2024-08-19
AU2019261933A1 (en) 2020-12-03
EP4296285A3 (en) 2024-02-28
HRP20231367T1 (hr) 2024-02-16
LT3774897T (lt) 2023-11-10
JP7832987B2 (ja) 2026-03-18
WO2019212899A1 (en) 2019-11-07
MD3774897T2 (ro) 2024-02-29
TW202003573A (zh) 2020-01-16
ES2962715T3 (es) 2024-03-20
EP3774897A1 (en) 2021-02-17
AU2019261933B2 (en) 2025-12-18
KR20210013062A (ko) 2021-02-03
RS64747B1 (sr) 2023-11-30
US20250290143A1 (en) 2025-09-18
PL3774897T3 (pl) 2024-01-29
SI3774897T1 (sl) 2024-01-31

Similar Documents

Publication Publication Date Title
JP7832987B2 (ja) 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム
US12391752B2 (en) Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease
US12540358B2 (en) RNASET2 compositions and methods of treatment therewith
WO2019209942A1 (en) Methods and systems for characterizing severe crohn's disease
HK40098022A (en) Methods and systems for selection and treatment of patients with inflammatory diseases
HK40047054B (en) Methods and systems for selection and treatment of patients with inflammatory diseases
HK40047054A (en) Methods and systems for selection and treatment of patients with inflammatory diseases
HK40066650A (zh) Tl1a患者选择方法、系统和装置
EA047764B1 (ru) Способы, системы и устройства для выбора пациента в отношении tl1a
HK40043280A (en) Methods and systems for selection and treatment of patients with inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220425

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230808

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231114

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20231117

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7434

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240205